Skip to main content

Day: January 7, 2025

Devon Energy Schedules Fourth-Quarter and Full-Year 2024 Earnings Release and Conference Call

OKLAHOMA CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) — Devon Energy Corp. (NYSE: DVN) today announced it will report fourth-quarter and full-year 2024 results on Tuesday, Feb. 18, after the close of U.S. financial markets. The earnings release and presentation for the fourth-quarter 2024 results will be available on the company’s website at www.devonenergy.com. On Wednesday, Feb. 19, the company will hold a conference call at 10 a.m. CST (11 a.m. EST), which will consist primarily of answers to questions from analysts and investors. A webcast link to the conference call will be provided on Devon’s website at www.devonenergy.com. A replay will be available on the website following the call. ABOUT DEVON ENERGY Devon Energy is a leading oil and gas producer in the U.S. with a premier multi-basin portfolio headlined by a world-class acreage...

Continue reading

GCC Announces Q4 2024 Conference Call Details

CHIHUAHUA, Mexico, Jan. 07, 2025 (GLOBE NEWSWIRE) — GCC, S.A.B. de C.V. (BMV: GCC*), a leading producer of cement and concrete in the United States and Mexico, will host a conference call to review its fourth quarter 2024 earnings results on Wednesday, January 29 at 10:00 a.m. (ET). Earnings results for the quarter ended December 31, 2024, will be released on Tuesday, January 28, after market close. The call will be hosted by Enrique Escalante, CEO, and Maik Strecker, CFO, and can be accessed by dialing +1 (877) 407 0789 or +1 (201) 689 8562 for international calls. The conference ID is 13750646. The presentation and listen-only webcast will be available via the following link. A replay of the webcast will be available the same day at 2:00 p.m. (ET) until February 5 at 11:59 p.m. (ET). The replay can be accessed through this link...

Continue reading

Rethinking Diabetes Care: PatentVest Pulse Unveils Key Insights on the Expanding CGM Market and the Innovations Driving Change

Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) — PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, “Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape.” This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care. Diabetes is one of the most pressing global health challenges, affecting an estimated 537 million adults worldwide in 2021—a number projected to rise to 783 million by 2045. As the complexity of diabetes management grows, the need for continuous, real-time glucose monitoring has never been more critical. Continuous Glucose Monitors (CGMs) address these challenges by providing patients with timely insights into their glucose...

Continue reading

Kaldvik AS: Resignation of board member

Reykjavík, 7 January 2025:  Aðalsteinn Ingólfsson has today notified the board of directors that he resigns as board member of Kaldvik AS. Mr. Ingólfsson has been a member of the board of directors since September 2022. His resignation has been accepted and is effective immediately. On behalf of the company, the board of directors extends its gratitude to Aðalsteinn for his service and contributions over the past years. For further information, please contact:Contacts: Róbert Róbertsson, CFO of Kaldvik AS: +354 843 0086 (mobile) About Kaldvik ASKaldvik AS is one of the leading salmon farmers in Iceland. Kaldvik AS has a well-developed and fully integrated value-chain controlling all steps from hatchery to sales, enabling the group to provide its customer with a sustainable premium product. Kaldvik AS is headquartered in Iceland. This information...

Continue reading

Dassault Aviation: Total number of shares and voting rights – 31 12 24

DASSAULT AVIATION French corporation (société anonyme) with a share capital of 62,876,448.80 euros Headquarters: 9, Rond-Point des Champs-Élysées – Marcel Dassault 75008 PARIS 712 042 456 RCS Paris Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers)DateTotal number of sharesTotal number of voting rights12/31/2024 78,595,561Theoretical voting rights: 130,723,214 Exercisable voting rights: 130,326,152AttachmentTotal number of shares and voting rights – 31 12 24

Continue reading

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

IRVINE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering closed on January 7, 2025. The offering consisted of 40,000,000 Common Units, each consisting of (i) one (1) share of Common Stock, (ii) one (1) Series A Registered Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $0.625 (the “Series A Warrants”) and (iii) one (1) Series B Registered Common Warrant...

Continue reading

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollment Positive data from first four patients announced December 2024 NXC-201 is the only one-time CAR-T therapy in development for AL Amyloidosis Next program update Q1 2025 AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow affecting ~33,000 patients in the U.S.LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced successful completion of the six-patient Phase 1b safety run-in segment in the U.S. NEXICART-2 study of NXC-201, an investigational CAR-T therapy, in patients relapsed/refractory (R/R) AL Amyloidosis....

Continue reading

The Days of Trend-Chasing Are Over: New Research from Sprout Social Reveals a Third of Consumers Think Jumping on Viral Trends is “Embarrassing” for Brands

The 2025 Sprout Social Index reveals what people now expect from brands on social media, the stakes of getting it wrong, and what marketers should do differently in the new year CHICAGO , Jan. 07, 2025 (GLOBE NEWSWIRE) — According to The 2025 Sprout Social Index™ Edition XX released today, social media has become the #1 source for keeping up with trends and cultural moments, ranking ahead of TV, family and friends, and every other digital channel. While this shift gives culturally aware brands a greater opportunity to land in people’s feeds, it also means attention is harder than ever to earn, especially in an increasingly saturated social landscape. To avoid getting lost in the noise, brands must move beyond surface-level trend-chasing and instead provide original, human-centric content and personalized, 1:1 engagements—...

Continue reading

XWELL Announces Senior Leadership Appointments and Changes

Ian Brown Appointed XWELL’s CFO Succeeding Suzanne Scrabis Peter Vermeulen Joins XWELL as its New Head of Human Resources Mike Heronime Joins XWELL as its New Marketing Director NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today announced new senior leadership appointments to support the Company’s strategic growth and business objectives. Ian Brown joined the Company as its new Chief Financial Officer on January 6, 2025, succeeding Suzanne Scrabis, whose separation is effective as of January 8, 2025. Mr. Brown has deep financial expertise and a proven track record in operational excellence, business operations and mergers and acquisitions. XWELL announced that in connection with Mr. Brown’s employment...

Continue reading

Inspirato Announces Plans to Expand Its Curated Portfolio of Residences and Destinations

The luxury travel club targets new destinations across Europe, Caribbean, California, U.S. East Coast, Mountain and Ski destinations and more DENVER, Jan. 07, 2025 (GLOBE NEWSWIRE) — Inspirato Incorporated (“Inspirato” or the “Company”) (NASDAQ: ISPO), the premier members-only luxury vacation club is excited to share its plans for significant expansion in 2025 and beyond. This initiative intends to add new homes in some of the world’s most sought-after destinations while enhancing its portfolio in key existing markets to provide members with a truly unparalleled travel experience. New & Expanded DestinationsEurope: Amalfi Coast, Bodrum, Capri, Côte d’Azur, Istanbul, Mallorca, Mykonos, Paris, Podgorica, Sardinia Caribbean: St. Barts, St. John, St. Thomas, Turks & Caicos California: Beverly Hills, La Jolla, Malibu,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.